In addition, in TNBC patients, expression of programmed death ligand 1 (PD-L1) occurs mainly on tumor-infiltrating immune cells rather than on tumor cells, suggesting that disruption of the programmed death 1 (PD-1)/PD-L1 interaction may be a useful treatment strategy for TNBCs [16,17,18,19]. The gene discussed is CD274; the disease is neoplasm.